BioGend Therapeutics

Founded in 2016, Biogend (Stock code: 6733.TW)  focuses on the development of advanced orthopedic products and is aiming to provide orthopedic medical services in all domains.

Core Product Portfolio:

• RevoCart:  The only one-step cartilage regeneration surgery in the world. A global leader in one-step autologous cartilage repair with a 16+ year clinical track record and 1,000+ successful cases. Currently covers all major medical centers in Taiwan, with active expansion into the Hong Kong and U.S. markets.

• OIF (Osteo-Inductive Factor, a rhBMP-2 product, bone growth factor)：Can be applied to regenerate bones such as long bones, spine, and tooth. Completed Phase II trials for tibial and non-union fractures. Expanding into dental and spinal fusion indications with high market growth potential.

• Softcut： Received TFDA Class II clearance in March 2026 for soft tissue repair in plastic surgery and OB/GYN, accelerating entry into the SVF (Stromal Vascular Fraction) market.

• Menocik & Fluzole： Targeted solutions for critical care infections, providing the company with stable and consistent cash flow.

Biogend has professional teams in multi-functions. It's seeking high-potential technologies and assisting innovative product development through project management, providing one-stop CDMO services.